CD80 and neoplasm: The absence of upregulation of MHC class I and II, CD80 and CD86 expression on the tumour cells following cisplatin supports the notion that cisplatin does not exert its immune effect by modulation of MHC or co-stimulatory molecules on the tumour cells.